<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4991">
  <stage>Registered</stage>
  <submitdate>4/05/2015</submitdate>
  <approvaldate>4/05/2015</approvaldate>
  <nctid>NCT02454842</nctid>
  <trial_identification>
    <studytitle>Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC</studytitle>
    <scientifictitle>A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor</scientifictitle>
    <utrn />
    <trialacronym>TH-4000</trialacronym>
    <secondaryid>TH-CR-601</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-small Cell Lung Cancer</healthcondition>
    <healthcondition>NSCLC</healthcondition>
    <healthcondition>Non-squamous NSCLC</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TH-4000 (Tarloxotinib)

Experimental: TH-4000 (Tarloxotinib) - TH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity


Treatment: drugs: TH-4000 (Tarloxotinib)
TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with response rate as evaluated by RECIST criteria</outcome>
      <timepoint>Approximately 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events (AEs)</outcome>
      <timepoint>Up to 30 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Type of adverse events (AEs)</outcome>
      <timepoint>Up to 30 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Severity of adverse events (AEs)</outcome>
      <timepoint>Up to 30 days after last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DOR) calculated for all patients achieving an objective response</outcome>
      <timepoint>Approximately 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival (PFS)</outcome>
      <timepoint>Approximately 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>Approximately 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to peak plasma concentration (Tmax) - Time to peak plasma concentration (Tmax), maximum plasma concentration (Cmax), area under concentration-time curve (AUC)</outcome>
      <timepoint>Cycle 1 Day 1 predose and up to 24 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum plasma concentration (Cmax)</outcome>
      <timepoint>Cycle 1 Day 1 predose and up to 24 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under concentration-time curve (AUC)</outcome>
      <timepoint>Cycle 1 Day 1 predose and up to 24 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>QTc Interval</outcome>
      <timepoint>Screening, Cycle 1 Day 1, 8, 15 &amp; 22, Day 1 of subsequent cycles</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key Eligibility Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Confirmed recurrent Stage IV NSCLC which progressed while on treatment with EGFR TKI

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors version
             1.1 (RECIST 1.1)

          -  Documented evidence of an EGFR mutation known to be associated with an EGFR TKI
             sensitivity

          -  No T790M mutation or small cell transformation including an assessment from tumor
             biopsy obtained while on or subsequent to the most recent EGFR TKI therapy

          -  Acceptable laboratory results as indicated by protocol

          -  Acceptable cardiac function as indicated by protocol

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Receiving medication that prolongs QT interval, with a risk of causing Torsades de
             Pointes (TdP) unless ECG meets inclusion criteria while on a stable dose of the
             medication

          -  Family history of long QTc syndrome

          -  Symptomatic central nervous system (CNS) lesions

          -  Radiation therapy within 2 weeks prior to the first dose of study medication

          -  Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose
             of study medication

          -  Concurrent active malignancy requiring systemic treatment

          -  Any other serious uncontrolled medical disorders or psychological conditions that may
             interfere with study conduct including but not limited to: clinically significant
             active infection (e.g., tuberculosis, viral hepatitis, human immunodeficiency virus
             [HIV]), recent (within 6 months) myocardial infarction or unstable angina, congestive
             heart failure, poorly-controlled hypertension or diabetes, concurrent active
             malignancy, or psychiatric condition that may interfere with the patient's ability to
             follow study procedures

          -  Pregnant or breast-feeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>37</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/01/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCullum - Melbourne</hospital>
    <postcode>3002 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Threshold Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This phase 2 study is designed to evaluate the safety and activity of TH-4000 (Tarloxotinib),
      a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced non-small
      cell lung cancer (NSCLC).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02454842</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen Liu</name>
      <address>Georgetown University Hospital Cancer Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>